PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V. (PHVS) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.7) | B- (2.9) | B- (2.9) | A+ (5.0) | B- (3.0) |
| 2026-11-07 | C+ (2.5) | D+ (1.8) | B- (2.9) | B- (3.1) | A+ (5.0) | B- (3.1) |
| 2026-10-31 | C+ (2.5) | D+ (1.8) | B- (2.9) | B- (3.1) | A+ (5.0) | B- (3.1) |
| 2026-10-24 | C+ (2.5) | D+ (1.8) | B- (2.9) | B- (2.9) | A+ (5.0) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe